Tff Pharmaceuticals, Inc. Stock Price, News & Analysis

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced successful treatment of a second patient with Voriconazole Inhalation Powder (TFF VORI) through a compassionate use program in Melbourne, Australia. This follows the presentation of positive results from the first patient at the 15th Annual International Congress on Lung Transplantation. TFF VORI, a dry powder formulation of voriconazole, aims to treat Invasive Pulmonary Aspergillosis (IPA). After six weeks of therapy, the second patient showed stabilized lung function and negative cultures for aspergillus, supporting TFF VORI's safety and efficacy advantages.

TFF Pharmaceuticals, Inc. (TFFP) announced updates on its clinical programs for Voriconazole Inhaled Powder (TFF VORI) and Tacrolimus Inhaled Powder (TFF TAC) on November 1, 2022. Preliminary data from Phase 2 studies is expected in Q1 2023 for TFF VORI and Q2 2023 for TFF TAC, but timelines have been impacted by staffing shortages and supply chain delays. TFF's CEO emphasized the ongoing commitment to overcoming these challenges while highlighting the potential benefits of TFF technology for targeted drug delivery.

TFF Pharmaceuticals (NASDAQ: TFFP) announced two poster presentations featuring its patented Thin Film Freezing (TFF) technology at the AAPS PharmSci 360 Meeting in Boston, scheduled for October 16-19, 2022. The presentations highlight the use of TFF in developing dry powder inhaled formulations of monoclonal antibodies, including anti-SARS-CoV-2 and anti-PD-1 antibodies. Additionally, the company will discuss applications of artificial intelligence in optimizing aerosol performance. TFF's technology aims to enhance the bioavailability and efficiency of drug delivery.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced participation of President and CEO Glenn Mattes at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. The company will also hold one-on-one meetings during the event. TFF Pharmaceuticals focuses on innovating drug delivery through its patented Thin Film Freezing (TFF) technology, which can convert various compounds into dry powder formulations with enhanced bioavailability and safety. The technology aims to revolutionize drug administration across multiple routes.

TFF Pharmaceuticals (TFFP) announced that two of its research abstracts, focusing on Thin Film Freezing (TFF) technology, have been accepted for presentation at the AAPS PharmSci 360 Meeting in October 2022. The studies emphasize TFF’s potential for producing stable dry powder inhaled formulations of monoclonal antibodies and utilizing machine learning to predict aerosol performance. These advancements highlight TFF's commitment to enhancing drug delivery systems and expanding its collaborations in biologics.

TFF Pharmaceuticals reported promising results from the compassionate use of its inhaled Voriconazole Powder (TFF VORI) for a lung transplant patient intolerant to oral therapy. Presented by Dr. Bradley Gardiner at the 15th International Congress on Lung Transplantation, TFF VORI has been successfully administered since February 2022, stabilizing the patient’s lung function without the toxicities associated with oral voriconazole. The treatment underscores the potential safety and efficacy of TFF VORI, with expectations of further validation in ongoing Phase 2 studies.

TFF Pharmaceuticals (NASDAQ: TFFP) announced that President and CEO Glenn Mattes will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace. Mattes will present on September 12 at 5:00 PM EST and will engage in one-on-one meetings throughout the event. The conference will highlight TFF's Thin Film Freezing (TFF) technology, which transforms drugs into more effective dry powder formulations. A webcast of the presentation will be available for 90 days following the event.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) provided a Q2 2022 update, reporting cash reserves of $20.9 million. R&D and G&A expenses rose to $5.1 million and $3.7 million respectively, contributing to a net loss of $8.7 million. The company is advancing its Phase 2 studies for Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder, highlighting significant industry partnerships with three top 20 pharma companies. A new R&D facility in Austin, Texas, enhances their operational capacity. Ongoing feasibility studies show promise for next-generation vaccines using Thin Film Freezing technology.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced a conference call scheduled for August 11, 2022, at 4:30 PM ET, to discuss its second quarter financial results and recent developments. The call will include a Q&A session for investors. The company is known for its innovative Thin Film Freezing (TFF) technology, which transforms drugs into dry powders for enhanced delivery and efficacy. Despite ongoing advancements, the company faces challenges, including the lack of FDA approvals for its products and uncertainties surrounding clinical testing outcomes.